EMA Application withdrawn: Biferonex (interferon beta-1a) — BioPartners GmbH

View source ↗

Summary

The EMA withdrew the application for Biferonex (interferon beta-1a) by BioPartners GmbH for multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Biferonex (interferon beta-1a)

Snippet

Status: Application withdrawn. Therapeutic area: Multiple Sclerosis. MAH: BioPartners GmbH. Decision date: 31/12/2009